Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Coherus Oncology (Nasdaq: CHRS) has scheduled its second quarter 2025 financial results release for August 7, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a business update.
Investors can access the conference call through toll-free (800-715-9871) or international (646-307-1963) dial-in numbers using Conference ID 8712736. A live webcast and archived replay will be available on the company's investor relations website.
Coherus Oncology (Nasdaq: CHRS) ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025, dopo la chiusura del mercato. La società terrà una teleconferenza e una diretta web alle 17:00 EDT dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla teleconferenza chiamando i numeri gratuiti (800-715-9871) o internazionali (646-307-1963) utilizzando l'ID conferenza 8712736. La diretta web e la registrazione saranno disponibili sul sito web delle relazioni con gli investitori della società.
Coherus Oncology (Nasdaq: CHRS) ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia y una transmisión en vivo a las 5:00 p.m. EDT del mismo día para discutir los resultados y ofrecer una actualización del negocio.
Los inversionistas pueden acceder a la llamada de conferencia mediante los números gratuitos (800-715-9871) o internacionales (646-307-1963) utilizando el ID de conferencia 8712736. La transmisión en vivo y la repetición archivada estarán disponibles en el sitio web de relaciones con inversionistas de la compañía.
Coherus Oncology (나스닥: CHRS)는 2025년 2분기 재무실적 발표를 2025년 8월 7일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 동부 표준시 오후 5시에 실적 발표 및 사업 현황 업데이트를 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 무료 전화번호(800-715-9871) 또는 국제 전화번호(646-307-1963)를 통해 컨퍼런스 ID 8712736를 사용하여 컨퍼런스 콜에 참여할 수 있습니다. 실시간 웹캐스트와 녹화된 다시보기는 회사의 투자자 관계 웹사이트에서 제공됩니다.
Coherus Oncology (Nasdaq : CHRS) a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025, après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 17h00 EDT le même jour pour discuter des résultats et fournir une mise à jour commerciale.
Les investisseurs peuvent accéder à la conférence téléphonique via les numéros gratuits (800-715-9871) ou internationaux (646-307-1963) en utilisant l'identifiant de conférence 8712736. Une webdiffusion en direct et un replay archivés seront disponibles sur le site des relations investisseurs de la société.
Coherus Oncology (Nasdaq: CHRS) hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr EDT eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren können über gebührenfreie Nummern (800-715-9871) oder internationale Nummern (646-307-1963) mit der Konferenz-ID 8712736 an der Telefonkonferenz teilnehmen. Ein Live-Webcast sowie eine Archiv-Wiedergabe werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, August 7, 2025, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call:
- TOLL-FREE DIAL-IN: (800) 715-9871
- INTERNATIONAL DIAL-IN: (646) 307-1963
- Conference ID 8712736
Webcast: https://edge.media-server.com/mmc/p/skv7e6d2
The press release with the second quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners’, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
Coherus Contact Information
Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
FAQ
When will Coherus Oncology (CHRS) report Q2 2025 earnings?
How can investors access Coherus Oncology's Q2 2025 earnings call?
Where can I find Coherus Oncology's Q2 2025 earnings materials?
Will there be a replay of Coherus Oncology's Q2 2025 earnings call?
